The Relationship Between Trichotillomania and Serum Brain-Derived Neurotrophic Factor Levels in Children and Adolescents: A Case-Control Study
Conclusions
Low serum BDNF was associated with TTM and the severity thereof. Furthermore, more extensive studies are needed to elucidate this association. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Cilostazol Administration for Subarachnoid Hemorrhage: A Meta-analysis of Randomized Controlled Trials
Conclusions
Cilostazol treatment may be effective to treat subarachnoid hemorrhage in the terms of symptomatic vasospasm, cerebral infarction, no or mild angiographic vasospasm, and an mRS score of 2 or less. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Probable Miglustat-Induced Psychosis in a Child With Niemann-Pick Type C
Conclusion
Although a positive effect of miglustat on neurological and psychiatric symptoms has been reported, there exists a risk of psychosis being triggered. To the best of our knowledge, this is the first case of pediatric NP-C to develop psychosis after miglustat to be reported in literature. Further studies of such cases are needed to understand the impact of miglustat on psychiatric symptoms in NP-C. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Case Reports Source Type: research
Probable Methylphenidate-Related Reversible “Visual Snow” in a Child With ADHD
Conclusions
Although remaining rare, prescribers ought to be cognizant of such unusual methylphenidate-related perceptual alterations. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Case Reports Source Type: research
The Pharmacotherapeutic Landscape for Essential Tremor: Quantifying the Level of Unmet Need From a Patient and Epidemiologic Perspective
Essential tremor (ET) is one of the most common neurological diseases. Despite this high prevalence, treatment options remain limited. Recent advances in mechanistic research have led to renewed interest in developing newer pharmacotherapeutic agents. Although this is promising, there remains surprisingly little knowledge of the magnitude of the vast ET patient population who would benefit from and/or engage with such agents. This is because the vast bulk of ET patients in the population has milder tremor and does not seek medical care for their tremor. How many of these would be interested in taking a new agent? Hence, th...
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Review Article Source Type: research
Clozapine Use in a Movement Disorder Clinic
Conclusions
When comparing clozapine use in this clinic as compared with others, we deduce that clozapine is likely significantly underutilized in the United States. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Akathisia Among Patients Undergoing Antipsychotic Therapy: Prevalence, Associated Factors, and Psychiatric Impact
Conclusions
Despite the high psychiatric and social burden of akathisia, it remains largely underdiagnosed and undertreated, because in part of its subjective component. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients With Parkinson Disease: An Open-Label Randomized Controlled Trial
This study aimed to compare the effects of different antidepressant therapies on depression in patients with Parkinson disease (PD) and to provide a reference for clinical treatment.
Methods
A total of 328 patients with idiopathic PD were selected consecutively. Subjects met Diagnostic and Statistical Manual of Mental Disease, Fourth Edition, criteria for a depressive disorder, or operationally defined subsyndromal depression, and scored greater than 17 on the 17-item Hamilton Depression Scale (HAMD-17). One hundred thirty-one patients with PD accompanied with depression were enrolled into the experimental group. Th...
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Yerbamate Tea Consumption: A Protective Factor in Parkinson Disease
Conclusions
This multicenter study highlights the association between an environmental factor, the YMT tea drinking, and PD. Although more evidence from longitudinal studies is needed, the results obtained here points toward a protective effect of the YMT tea concentration per serving on PD. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Antipsychotic-Induced Hypothermia After Starting Aripiprazole for Posttraumatic Agitation Management: A Case Report
Conclusions
To our knowledge, this is the first publication detailing antipsychotic-induced hypothermia occurring in a TBI patient. Clinicians who initiate antipsychotics for posttraumatic agitation in a TBI patient should be aware of this potential adverse effect, as well as clinical presentation, evaluation, and management strategies. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Case Reports Source Type: research
Brexpiprazole-Associated Pisa Syndrome (Pleurothotonus) in a Patient With Dementia
Conclusions
Drug-induced PS may be associated with dopamine-acetylcholine imbalance. This imbalance causes the dysfunction of the cortex and basal ganglia and the dysfunction of sensory and somatosensory system. Stopping the offending drugs is a choice for the treatment of PS. This is the first report of PS-induced brexpiprazole. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Case Reports Source Type: research
What Is the Medication Iatrogenic Risk in Elderly Outpatients for Chronic Pain?
Conclusion
Elderly patients with chronic pain are at risk of medication iatrogeny. Preventive measures as multidisciplinary medication review could reduce the iatrogenic risk in these outpatients.
This study is registered at clinicaltrials.gov as NCT04006444 on July 3, 2019. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study
Background
We hypothesized that rotigotine may have a positive effect on cognitive function in patients with Parkinson disease (PD) by improving daytime motor function and sleep status.
Methods
Fifteen PD patients with sleep disturbances, defined as a PD Sleep Scale (PDSS)-2 score of 15 or greater, were included in this single-center, 3-month open-label study. Participants received 2 to 4 mg/24 h (patch content: 4.5–9 mg) rotigotine for a 3-month period. At baseline and 3 months, the patients were evaluated on the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts III and IV an...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder
Conclusions
Switching to suvorexant or eszopiclone was well tolerated and improved the severity of benzodiazepine-unresponsive insomnia in MDD patients. Both drugs could be beneficial alternatives to benzodiazepines for treating insomnia in MDD patients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina
Objective
Escalation (ES) and early high-efficacy (EHE) therapies have been the main treatment strategies adopted in multiple sclerosis (MS) in recent years. The aim of this study was to compare the effectiveness and safety of EHE versus ES strategies in MS patients from Argentina.
Methods
This is a retrospective multicenter cohort study in Argentina. Eligible patients were categorized into 2 groups as follows: EHE if received natalizumab, ocrelizumab, rituximab, alemtuzumab, mitoxantrone, or cladribine; and ES if received interferon β, glatiramer acetate, teriflunomide, dimethyl fumarate, or fingolimod as init...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
